L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia

Jacques Baillargeon, Anne Marie Langevin, Margaret Lewis, Paul J. Thomas, Judith Mullins, John Dugan, Bradley H Pollock

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND. The objective of the current study was to compare chemotherapy dose modifications in obese (a body mass index [BMI] > 95%) and nonobese (a BMI ≤ 95%) pediatric patients with acute lymphoblastic leukemia (ALL). METHODS. The study cohort was comprised of 199 pediatric patients diagnosed with ALL who were treated at 1 of 2 South Texas pediatric oncology centers between 1990-2000. The relative chemotherapy dose modification during the induction phase of chemotherapy was calculated as the ratio of 1) the actual administered dose of L-asparaginase and 2) the protocol-calculated dose of L-asparaginase. The extent to which the chemotherapy dose modification varied according to obesity status was assessed using stratified Student t tests and an ordinary least-squares regression analysis. RESULTS. Obese ALL patients were found to exhibit a 7% decrease in the mean relative modification of L-asparaginase during induction chemotherapy compared with their nonobese counterparts. This finding was statistically significant (P = 0.009), even after adjustment for gender, age, ethnicity, and clinical institution. CONCLUSIONS. To the authors' knowledge, the current study is the first published report of an obesity-associated chemotherapy dose modification in pediatric patients with ALL, the most common childhood malignancy. It will be important to examine whether these findings are consistent with those observed in future studies, and ultimately to assess the association between obesity-related dose modifications and long-term cancer outcomes.

Original languageEnglish (US)
Pages (from-to)2858-2861
Number of pages4
JournalCancer
Volume104
Issue number12
DOIs
StatePublished - Dec 15 2005
Externally publishedYes

Fingerprint

Asparaginase
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Drug Therapy
Induction Chemotherapy
Obesity
Body Mass Index
Least-Squares Analysis
Neoplasms
Cohort Studies
Regression Analysis
Students

Keywords

  • Acute lymphoblastic leukemia (ALL); body mass index (BMI)
  • Cancer risk
  • Hispanic
  • Obesity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Baillargeon, J., Langevin, A. M., Lewis, M., Thomas, P. J., Mullins, J., Dugan, J., & Pollock, B. H. (2005). L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia. Cancer, 104(12), 2858-2861. https://doi.org/10.1002/cncr.21584

L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia. / Baillargeon, Jacques; Langevin, Anne Marie; Lewis, Margaret; Thomas, Paul J.; Mullins, Judith; Dugan, John; Pollock, Bradley H.

In: Cancer, Vol. 104, No. 12, 15.12.2005, p. 2858-2861.

Research output: Contribution to journalArticle

Baillargeon, J, Langevin, AM, Lewis, M, Thomas, PJ, Mullins, J, Dugan, J & Pollock, BH 2005, 'L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia', Cancer, vol. 104, no. 12, pp. 2858-2861. https://doi.org/10.1002/cncr.21584
Baillargeon J, Langevin AM, Lewis M, Thomas PJ, Mullins J, Dugan J et al. L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia. Cancer. 2005 Dec 15;104(12):2858-2861. https://doi.org/10.1002/cncr.21584
Baillargeon, Jacques ; Langevin, Anne Marie ; Lewis, Margaret ; Thomas, Paul J. ; Mullins, Judith ; Dugan, John ; Pollock, Bradley H. / L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia. In: Cancer. 2005 ; Vol. 104, No. 12. pp. 2858-2861.
@article{def0ebe3b3f94f62a856c6298b927afd,
title = "L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia",
abstract = "BACKGROUND. The objective of the current study was to compare chemotherapy dose modifications in obese (a body mass index [BMI] > 95{\%}) and nonobese (a BMI ≤ 95{\%}) pediatric patients with acute lymphoblastic leukemia (ALL). METHODS. The study cohort was comprised of 199 pediatric patients diagnosed with ALL who were treated at 1 of 2 South Texas pediatric oncology centers between 1990-2000. The relative chemotherapy dose modification during the induction phase of chemotherapy was calculated as the ratio of 1) the actual administered dose of L-asparaginase and 2) the protocol-calculated dose of L-asparaginase. The extent to which the chemotherapy dose modification varied according to obesity status was assessed using stratified Student t tests and an ordinary least-squares regression analysis. RESULTS. Obese ALL patients were found to exhibit a 7{\%} decrease in the mean relative modification of L-asparaginase during induction chemotherapy compared with their nonobese counterparts. This finding was statistically significant (P = 0.009), even after adjustment for gender, age, ethnicity, and clinical institution. CONCLUSIONS. To the authors' knowledge, the current study is the first published report of an obesity-associated chemotherapy dose modification in pediatric patients with ALL, the most common childhood malignancy. It will be important to examine whether these findings are consistent with those observed in future studies, and ultimately to assess the association between obesity-related dose modifications and long-term cancer outcomes.",
keywords = "Acute lymphoblastic leukemia (ALL); body mass index (BMI), Cancer risk, Hispanic, Obesity",
author = "Jacques Baillargeon and Langevin, {Anne Marie} and Margaret Lewis and Thomas, {Paul J.} and Judith Mullins and John Dugan and Pollock, {Bradley H}",
year = "2005",
month = "12",
day = "15",
doi = "10.1002/cncr.21584",
language = "English (US)",
volume = "104",
pages = "2858--2861",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia

AU - Baillargeon, Jacques

AU - Langevin, Anne Marie

AU - Lewis, Margaret

AU - Thomas, Paul J.

AU - Mullins, Judith

AU - Dugan, John

AU - Pollock, Bradley H

PY - 2005/12/15

Y1 - 2005/12/15

N2 - BACKGROUND. The objective of the current study was to compare chemotherapy dose modifications in obese (a body mass index [BMI] > 95%) and nonobese (a BMI ≤ 95%) pediatric patients with acute lymphoblastic leukemia (ALL). METHODS. The study cohort was comprised of 199 pediatric patients diagnosed with ALL who were treated at 1 of 2 South Texas pediatric oncology centers between 1990-2000. The relative chemotherapy dose modification during the induction phase of chemotherapy was calculated as the ratio of 1) the actual administered dose of L-asparaginase and 2) the protocol-calculated dose of L-asparaginase. The extent to which the chemotherapy dose modification varied according to obesity status was assessed using stratified Student t tests and an ordinary least-squares regression analysis. RESULTS. Obese ALL patients were found to exhibit a 7% decrease in the mean relative modification of L-asparaginase during induction chemotherapy compared with their nonobese counterparts. This finding was statistically significant (P = 0.009), even after adjustment for gender, age, ethnicity, and clinical institution. CONCLUSIONS. To the authors' knowledge, the current study is the first published report of an obesity-associated chemotherapy dose modification in pediatric patients with ALL, the most common childhood malignancy. It will be important to examine whether these findings are consistent with those observed in future studies, and ultimately to assess the association between obesity-related dose modifications and long-term cancer outcomes.

AB - BACKGROUND. The objective of the current study was to compare chemotherapy dose modifications in obese (a body mass index [BMI] > 95%) and nonobese (a BMI ≤ 95%) pediatric patients with acute lymphoblastic leukemia (ALL). METHODS. The study cohort was comprised of 199 pediatric patients diagnosed with ALL who were treated at 1 of 2 South Texas pediatric oncology centers between 1990-2000. The relative chemotherapy dose modification during the induction phase of chemotherapy was calculated as the ratio of 1) the actual administered dose of L-asparaginase and 2) the protocol-calculated dose of L-asparaginase. The extent to which the chemotherapy dose modification varied according to obesity status was assessed using stratified Student t tests and an ordinary least-squares regression analysis. RESULTS. Obese ALL patients were found to exhibit a 7% decrease in the mean relative modification of L-asparaginase during induction chemotherapy compared with their nonobese counterparts. This finding was statistically significant (P = 0.009), even after adjustment for gender, age, ethnicity, and clinical institution. CONCLUSIONS. To the authors' knowledge, the current study is the first published report of an obesity-associated chemotherapy dose modification in pediatric patients with ALL, the most common childhood malignancy. It will be important to examine whether these findings are consistent with those observed in future studies, and ultimately to assess the association between obesity-related dose modifications and long-term cancer outcomes.

KW - Acute lymphoblastic leukemia (ALL); body mass index (BMI)

KW - Cancer risk

KW - Hispanic

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=29144499340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144499340&partnerID=8YFLogxK

U2 - 10.1002/cncr.21584

DO - 10.1002/cncr.21584

M3 - Article

C2 - 16288492

AN - SCOPUS:29144499340

VL - 104

SP - 2858

EP - 2861

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -